ES2657060T3 - Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas - Google Patents
Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas Download PDFInfo
- Publication number
- ES2657060T3 ES2657060T3 ES14734831.2T ES14734831T ES2657060T3 ES 2657060 T3 ES2657060 T3 ES 2657060T3 ES 14734831 T ES14734831 T ES 14734831T ES 2657060 T3 ES2657060 T3 ES 2657060T3
- Authority
- ES
- Spain
- Prior art keywords
- fusokines
- receptor binding
- binding affinities
- strongly reduced
- cytokines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000695 Cytokines Proteins 0.000 title abstract 7
- 102000004127 Cytokines Human genes 0.000 title abstract 7
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 abstract 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306034 | 2013-07-18 | ||
| EP13306034 | 2013-07-18 | ||
| PCT/EP2014/064227 WO2015007536A2 (en) | 2013-07-18 | 2014-07-03 | Fusokines involving cytokines with strongly reduced receptor binding affinities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2657060T3 true ES2657060T3 (es) | 2018-03-01 |
Family
ID=48906191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14734831.2T Active ES2657060T3 (es) | 2013-07-18 | 2014-07-03 | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas |
| ES17195867T Active ES2757501T3 (es) | 2013-07-18 | 2014-07-03 | Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17195867T Active ES2757501T3 (es) | 2013-07-18 | 2014-07-03 | Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10640542B2 (enExample) |
| EP (2) | EP3022305B1 (enExample) |
| JP (2) | JP6580037B2 (enExample) |
| KR (1) | KR102322510B1 (enExample) |
| CN (2) | CN110835376B (enExample) |
| AU (2) | AU2014292371B2 (enExample) |
| BR (1) | BR112016001036B1 (enExample) |
| CA (1) | CA2917937C (enExample) |
| DK (1) | DK3299466T3 (enExample) |
| ES (2) | ES2657060T3 (enExample) |
| IL (1) | IL243451B (enExample) |
| MX (1) | MX375441B (enExample) |
| SG (2) | SG11201600163VA (enExample) |
| WO (1) | WO2015007536A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN115850521A (zh) | 2016-02-05 | 2023-03-28 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| WO2017153402A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| CA3050601A1 (en) * | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CA3069930A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
| AU2018313810B2 (en) | 2017-08-09 | 2025-05-15 | Orionis Biosciences BV | Clec9A binding agents and use thereof |
| CN111328286B (zh) | 2017-08-09 | 2024-08-23 | 奥里尼斯生物科学有限公司 | Pd-1和pd-l1结合剂 |
| CN111556757A (zh) | 2017-10-31 | 2020-08-18 | 西方溶瘤细胞有限公司 | 用于全身递送的平台溶瘤载体 |
| EP3743448A4 (en) | 2018-01-26 | 2021-11-03 | Orionis Biosciences, Inc. | XCR1 BINDING AGENTS AND USES THEREOF |
| US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| CA3108795A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | Sirp1a targeted chimeric proteins and uses thereof |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| WO2022011005A1 (en) * | 2020-07-07 | 2022-01-13 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
| EP4247410A4 (en) | 2020-11-19 | 2025-05-07 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| EP4622660A1 (en) * | 2022-11-21 | 2025-10-01 | Wisconsin Alumni Research Foundation | Synthetic il6-il1 beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3115318B2 (ja) | 1989-08-22 | 2000-12-04 | イミュネックス・コーポレーション | Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| DE60025832T2 (de) * | 1999-08-09 | 2006-08-31 | Emd Lexigen Research Center Corp., Billerica | Mehrere zytokin-antikörper komplexen |
| US20020177571A1 (en) * | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) * | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| MX2010003099A (es) | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| WO2010066740A1 (en) | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| JP2013504539A (ja) | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| CN105031618A (zh) * | 2009-11-02 | 2015-11-11 | 加利福尼亚大学董事会 | 用于细胞因子递送的穹窿体复合物 |
| JP5553906B2 (ja) * | 2009-12-23 | 2014-07-23 | グラダリス インク． | フューリンノックダウン及びｇｍ−ｃｓｆ増強（ｆａｎｇ）癌ワクチン |
| CA2796706A1 (en) * | 2010-04-22 | 2011-10-27 | The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center | High affinity leptins and leptin antagonists |
| CN102372780A (zh) * | 2010-08-23 | 2012-03-14 | 上海市计划生育科学研究所 | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CA2861927C (en) * | 2012-01-20 | 2021-01-26 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| EP3799880A3 (en) | 2012-03-03 | 2021-06-23 | ImmunGene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| IL251822B2 (en) * | 2014-10-29 | 2023-03-01 | Teva Pharmaceuticals Australia Pty Ltd | Variants of interferon alpha-2-b |
-
2014
- 2014-07-03 CN CN201911159381.7A patent/CN110835376B/zh active Active
- 2014-07-03 JP JP2016526515A patent/JP6580037B2/ja active Active
- 2014-07-03 BR BR112016001036-1A patent/BR112016001036B1/pt active IP Right Grant
- 2014-07-03 MX MX2016000611A patent/MX375441B/es active IP Right Grant
- 2014-07-03 SG SG11201600163VA patent/SG11201600163VA/en unknown
- 2014-07-03 ES ES14734831.2T patent/ES2657060T3/es active Active
- 2014-07-03 DK DK17195867T patent/DK3299466T3/da active
- 2014-07-03 AU AU2014292371A patent/AU2014292371B2/en active Active
- 2014-07-03 ES ES17195867T patent/ES2757501T3/es active Active
- 2014-07-03 US US14/905,343 patent/US10640542B2/en active Active
- 2014-07-03 CN CN201480040538.3A patent/CN105705641B/zh active Active
- 2014-07-03 CA CA2917937A patent/CA2917937C/en active Active
- 2014-07-03 EP EP14734831.2A patent/EP3022305B1/en active Active
- 2014-07-03 KR KR1020167002676A patent/KR102322510B1/ko active Active
- 2014-07-03 WO PCT/EP2014/064227 patent/WO2015007536A2/en not_active Ceased
- 2014-07-03 EP EP17195867.1A patent/EP3299466B1/en active Active
- 2014-07-03 SG SG10201808738WA patent/SG10201808738WA/en unknown
-
2016
- 2016-01-03 IL IL24345116A patent/IL243451B/en active IP Right Grant
-
2018
- 2018-06-01 AU AU2018203868A patent/AU2018203868B2/en active Active
- 2018-08-14 US US16/103,302 patent/US11358997B2/en active Active
-
2019
- 2019-08-27 JP JP2019154901A patent/JP6853317B2/ja active Active
-
2022
- 2022-04-29 US US17/733,026 patent/US12410222B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2657060T3 (es) | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas | |
| ES2627510T3 (es) | Biocompuesto o biomaterial con cáscaras/vainas de semillas de girasol | |
| ES2650463T3 (es) | Tratamiento de enfermedades inflamatorias con ACE2 | |
| AR118560A2 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| GB2562396A (en) | Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| GB2561496A (en) | Devices and methods for simulating a function of a liver tissue | |
| MX2018004475A (es) | Agentes biologicos y su uso en plantas. | |
| EP4368992A3 (en) | Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue | |
| BR112015016005A2 (pt) | preparação de amostra em um suporte sólido | |
| CO2017011487A2 (es) | Muteínas de interleuquina 2 para la expansión de células t regulatorias | |
| BR112015021993A8 (pt) | polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular | |
| CL2012003625A1 (es) | Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas. | |
| EA201170242A1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
| BR112012028805A2 (pt) | composições de endorribonuclease e métodos de uso das mesmas. | |
| CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| EP2558478A4 (en) | AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE | |
| MX2016002166A (es) | Anticuerpos. | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| BR112013003965A2 (pt) | uso de açúcares em uma matriz de estabilização e composições sólidas | |
| ES2616017T3 (es) | Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación | |
| CL2020000734A1 (es) | Expansión y uso de fracciones de células nk ampliadas. | |
| EP3880785A4 (en) | In vitro cell culture mucus systems | |
| BR112022006866A2 (pt) | Métodos para caracterizar proteínas de células hospedeiras | |
| IL294047A (en) | Antibodies against integrin alpha 11 beta 1 |